Excerpt from:
Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh